On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Karus Therapeutics (United Kingdom)

InstitutionResearch output, impact & collaborations

Karus Therapeutics (United Kingdom) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Karus Therapeutics (United Kingdom)?

ScholarIQrecord summary

Karus Therapeutics (United Kingdom) is a research organisation in Didcot, GB. OpenAlex records 86 works and 5,313 citations for it. 32 researchers list it as their most recent affiliation.

How many works does Karus Therapeutics (United Kingdom) have?

ScholarIQindexed works

Karus Therapeutics (United Kingdom) has 86 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Karus Therapeutics (United Kingdom) →

How many citations does Karus Therapeutics (United Kingdom) have?

ScholarIQcitation count

Karus Therapeutics (United Kingdom) has 5,313 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Karus Therapeutics (United Kingdom) →

How many researchers are at Karus Therapeutics (United Kingdom)?

ScholarIQresearcher count

Karus Therapeutics (United Kingdom) has 32 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Karus Therapeutics (United Kingdom)?

ScholarIQavg h-index

Karus Therapeutics (United Kingdom) has an average h-index of 115 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Karus Therapeutics (United Kingdom)?

ScholarIQror

The ROR for Karus Therapeutics (United Kingdom) is on the source record.

Open the ROR →

What is the OpenAlex record for Karus Therapeutics (United Kingdom)?

ScholarIQopenalex

The OpenAlex for Karus Therapeutics (United Kingdom) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Karus Therapeutics (United Kingdom)?

ScholarIQtop researchers by citations

Srđan Verstovšek · Myeloproliferative Neoplasms: Diagnosis and Treatment

1,624 works59,248 citations

What are the most-cited papers on Karus Therapeutics (United Kingdom)?

ScholarIQmost cited works

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators

Haematologica. 2015331 CitationsOPEN ACCESS

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian, Jason Gotlib, F. Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, V. Sandor, P. Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srđan Verstovšek, on behalf of the COMFORT Investigators

Haematologica. 2015257 CitationsOPEN ACCESS

How much of the research on Karus Therapeutics (United Kingdom) is open access?

ScholarIQopen access share

100%OPEN ACCESS

Gold

100%

Green

Hybrid

Bronze

Closed